Results 251 to 260 of about 145,467 (273)

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

New England Journal of Medicine, 2009
Stuart J Connolly, Michael D Ezekowitz, Salim Yusuf   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Lancet, The, 2014
Christian Ruff, Robert P Giugliano, Eugene Braunwald   +2 more
exaly   +2 more sources

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

New England Journal of Medicine, 2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.
Robert P Giugliano, Eugene Braunwald, Michael D Ezekowitz   +2 more
exaly   +2 more sources

Apixaban versus Warfarin in Patients with Atrial Fibrillation

New England Journal of Medicine, 2011
BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a ...
Christopher B Granger, John H Alexander, John J V Mcmurray   +2 more
exaly   +2 more sources

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

Circulation, 2015
David J Graham, Marsha E Reichman, Ting-Chang Sheu   +2 more
exaly   +2 more sources

Apixaban versus Warfarin in Patients with Left Ventricular Thrombus, A Prospective Multicenter Randomized Clinical Trial.

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
AIMS Current guidelines recommend anticoagulation with a vitamin K antagonist to treat left ventricular (LV) thrombus post myocardial infarction (MI). Data on the use of direct oral anticoagulants (DOACS) in this setting is limited.
R. Alcalai, A. Butnaru, G. Moravsky, O. Yagel, R. Rashad, Mahsati Ibrahimli, D. Planer, O. Amir, G. Elbaz‐Greener, D. Leibowitz   +9 more
semanticscholar   +1 more source

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

Circulation, 2014
Sam Schulman, Clive Kearon
exaly   +2 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

Clinical Pharmacology and Therapeutics, 2017
Julie A. Johnson, K. Caudle, L. Gong, Michelle Whirl‐Carrillo, C. Stein, S. Scott, M. M. Lee, B. Gage, S. Kimmel, M. Perera, Jeffrey L. Anderson, M. Pirmohamed, T. Klein, N. Limdi, L. Cavallari, M. Wadelius   +15 more
exaly   +2 more sources

Apixaban versus Warfarin in Patients with Atrial Fibrillation

, 2012
Shinya Goto
semanticscholar   +1 more source

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2015
Agnes Y Y Lee, P. Kamphuisen, Guy Meyer, Rupert Bauersachs, M. Janas, M. Jarner, A. Khorana   +6 more
semanticscholar   +1 more source